https://www.thebodypro.com/author/avac-global-advocacy-for-hiv-prevention

AVAC: Global Advocacy for HIV Prevention

AVAC: Global Advocacy for HIV Prevention was founded in December 1995 to advocate for the development of a safe, effective, and accessible HIV vaccine. It seeks to promote increased funding and investment in HIV vaccine research by government agencies, private industry and non-governmental organizations; to identify barriers to the development of a vaccine; and to increase public awareness about the need for a well funded, coordinated HIV vaccine research program. It seeks to promote increased HIV vaccine advocacy efforts by community-based organizations and increased awareness about HIV vaccine development among AIDS-affected communities. It is committed to the principle that funds for HIV vaccine research are not to be taken from basic HIV research, drug development or prevention efforts.

Latest by AVAC: Global Advocacy for HIV Prevention

3D Imaging Videos Show HIV Infection Might Establish Within Hours Img
Conference Coverage

3D Imaging Videos Show HIV Infection Might Establish Within Hours

A fascinating lecture at this year's HIVR4P conference showed how advances in modern scanning technologies can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distribute...

The Rise of Broadly Neutralizing Antibodies Img

The Rise of Broadly Neutralizing Antibodies

Research on broadly neutralizing antibodies is taking the field of HIV prevention science in new directions, with implications for new prevention interventions and vaccine development.

CROI 2018: Research for the Front Lines Img
News

CROI 2018: Research for the Front Lines

Rob Newells, executive director of the AIDS Project of the East Bay, gives his personal (U.S.-centered, black MSM-focused) highlights from CROI 2018.

CROI 2018: Highlights and What's Next for Advocates Img
CROI (Conference on Retroviruses and Opportunistic Infections)

CROI 2018: Highlights and What's Next for Advocates

This year's Conference on Retroviruses and Opportunistic Infections broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.

Snapshot From IAS 2017 Img
IAS (International AIDS Society) Conference

Snapshot From IAS 2017

"There is good news and bad news, often in the same story," AVAC writes.

Declining Funding and Shrinking Donor Base Imperils Continued Success of HIV Prevention Img
Viewpoints

Declining Funding and Shrinking Donor Base Imperils Continued Success of HIV Prevention

A new report documents 2016 funding and highlights a continuing trend of flat or declining funding and its potential impact on further innovation in HIV prevention research and development.

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug? Img

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug?

A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.

In the Face of Complex HIV Vaccine Research, the Ground Is Ripe for Renewed Advocacy and Activism Img
Viewpoints

In the Face of Complex HIV Vaccine Research, the Ground Is Ripe for Renewed Advocacy and Activism

"Good participatory practice and community voices are needed now more than ever in the HIV vaccine research arena," Daisy Ouya and Morenike Upkong write.

Next-Generation PrEP Trials: The Age of "Active Controls" Img

Next-Generation PrEP Trials: The Age of "Active Controls"

A medicine that can be administered once every two months to reduce HIV risk could be an option in the future if two big efficacy trials find good results.

CROI 2017: A View from My Seat at the Table Img
CROI (Conference on Retroviruses and Opportunistic Infections)

CROI 2017: A View from My Seat at the Table

"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."